- Home
- KLRS vs ATCH Comparison
KLRS vs ATCH Comparison
Compare KLRS & ATCH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KLRS
- ATCH
- Stock Information
- Founded
- KLRS 2019
- ATCH 2022
- Country
- KLRS United States
- ATCH United States
- Employees
- KLRS N/A
- ATCH N/A
- Industry
- KLRS Biotechnology: Biological Products (No Diagnostic Substances)
- ATCH
- Sector
- KLRS Health Care
- ATCH
- Exchange
- KLRS Nasdaq
- ATCH Nasdaq
- Market Cap
- KLRS 46.0M
- ATCH 46.1M
- IPO Year
- KLRS N/A
- ATCH N/A
- Fundamental
- Price
- KLRS $4.97
- ATCH $0.39
- Analyst Decision
- KLRS Strong Buy
- ATCH
- Analyst Count
- KLRS 2
- ATCH 0
- Target Price
- KLRS $23.00
- ATCH N/A
- AVG Volume (30 Days)
- KLRS 175.7K
- ATCH 47.5M
- Earning Date
- KLRS 11-15-2025
- ATCH 11-14-2025
- Dividend Yield
- KLRS N/A
- ATCH N/A
- EPS Growth
- KLRS N/A
- ATCH N/A
- EPS
- KLRS N/A
- ATCH 0.96
- Revenue
- KLRS N/A
- ATCH $10,856,612.00
- Revenue This Year
- KLRS N/A
- ATCH N/A
- Revenue Next Year
- KLRS N/A
- ATCH N/A
- P/E Ratio
- KLRS N/A
- ATCH $0.43
- Revenue Growth
- KLRS N/A
- ATCH 171.31
- 52 Week Low
- KLRS $2.14
- ATCH $0.14
- 52 Week High
- KLRS $24.15
- ATCH $26.94
- Technical
- Relative Strength Index (RSI)
- KLRS 49.92
- ATCH 47.31
- Support Level
- KLRS $4.70
- ATCH $0.39
- Resistance Level
- KLRS $5.30
- ATCH $0.54
- Average True Range (ATR)
- KLRS 0.41
- ATCH 0.04
- MACD
- KLRS -0.06
- ATCH 0.00
- Stochastic Oscillator
- KLRS 67.48
- ATCH 24.55
About KLRS Kalaris Therapeutics Inc. Common Stock
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.
About ATCH AtlasClear Holdings Inc. Common Stock
AtlasClear Holdings Inc is a fintech company. Its goal is to build a cutting-edge technology-enabled financial services firm that would create a more efficient platform for trading, clearing, settlement, and banking of evolving and financial products with a focus on financial services firms. It is a fintech-driven business-to-business platform that expects to power innovation in fintech, investing, and trading. The company believes it is positioned to provide a modern, mission-critical suite of solutions to its clients, enabling them to reduce their transaction costs and compete more effectively in their businesses.